Shares of Pieris Pharmaceuticals (PIRS) have fallen by 30% since my initial recommendation from August of 2017, where I highlighted management's partnering prowess as reflected in $4 billion in potential milestone payments the company stood to receive as multiple programs moved forward. The stock is also in the red by the same amount since my September 2018 update piece was published exclusively in ROTY.
ROTY member dsj.2018 brought this one to my attention again, noting that market capitalization of around $160 million with $120 million in cash indicated significant downside protection, while the